Drug Trial Radar · NCT00595049
Pulmonary Artery Remodelling With Bosentan
Last checked: Nov 20, 2026Latest source record: Jun 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
11
Actual
Start
May 31, 2006
Primary completion
Dec 31, 2008
Study completion Jun 30, 2010
Sponsor
- Lead sponsor
- ActelionJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Jan 16, 2008
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to investigate whether bosentan (Tracleer®) affects the wall thickness of the pulmonary arteries in patients with idiopathic pulmonary arterial hypertension (iPAH) and PAH related to systemic sclerosis (PAH-SSc). The second purpose is to investigate if bosentan affects the enlargement of small vessels in the lungs in response to natural chemicals in patients with iPAH and PAH-SSc.
Conditions
- Hypertension, Pulmonary
Interventions
bosentanDrug
Bosentan 62.5 mg bid for 4 weeks, then 125 mg bid
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline (BL) to 6 mths in the IVUS-derived measurement of pulmonary artery wall thickness.Time frame: Baseline to 6 months
- Change from BL to 6 mths in pulmonary microvascular circulation dilator responses to actylcholine (Ach).Time frame: Baseline to 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Royal Prince Alfred Hospital
Camperdown, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.